Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Aegerion Pharmaceuticals
October 04, 2016
Debt binge sees Aralez become a mini-Valeant
July 07, 2016
Genmab and Tesaro lead first-half gainers as Endo and Infinity falter
June 16, 2016
QLT and Aegerion put each other out of their miseries
November 24, 2015
Astra gives as well as taking away
January 08, 2015
Buoyant small pharma market hides some big losers
November 12, 2014
Debt-funded biotechs under the spotlight
November 06, 2014
An expensive distraction strategy for Aegerion
July 03, 2014
Market wobble fails to derail mid and small-caps
February 27, 2014
Lack of talk – for once – sees Aegerion’s shares fall
November 07, 2013
Small companies’ struggles sound a warning over in-house drug launches
April 25, 2013
Calling the top? Ever-rising valuations spark biotech worries
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
January 17, 2023
JP Morgan Healthcare Conference 2023
January 12, 2023
Evaluate Vantage 2023 Preview Infographic
Editor's Picks
February 01, 2023
Novartis trims its pipeline
January 30, 2023
The end of the Humira era
January 05, 2023
The biggest-selling drugs of 2023
January 31, 2023
Astrazeneca gets personal
February 06, 2023
The slow death of the medtech Spac deal